• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Optomed

1.65 EUR

-0.96 %

5,661 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.96 %
+6.86 %
-31.31 %
-56.18 %
-53.98 %
-56.92 %
-47.89 %
-87.53 %
-63.93 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
35.44M EUR
Turnover
197.02K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
07.05.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Yes, if you look at the big picture rather than just the current revenue, there are starting to be more arguments for an optimistic view than, for example, a year ago. Positive drivers: Largest order in history from the USA This is perhaps the most important individual signal. It...
17 hours ago
by Mr. Stock
25
Optomed has certainly convinced its customers of a stable partnership and a bright future within the framework of a successful major sales process. No one buys €1.8 million worth of hardware from an unstable or precarious operator. The AI component is also convincing and demands ...
23 hours ago
by Jummijammi2
20
Here are Atte’s comments regarding this large order Inderes – 22 Jun 26 Optomed sai 1,8 MEUR:n laitetilauksen Yhdysvalloista - Inderes Tilaus ylittää koko alkuvuoden laiteliikevaihdon ja vahvistaa kassaa.
7 hours ago
by Sijoittaja-alokas
19
I understand the point, but I think the conclusion is a bit too straightforward. From the release, it is not known whether the customer has rejected or would not implement the AI, or if this is a phased rollout where the hardware is acquired first and the software later. This operating...
yesterday
by Mr. Stock
19
People wonder about many things… It is the company’s largest order to date; personally, as a shareholder, I am quite satisfied. It underlines the market’s interest in handheld cameras. On the other hand, it builds a moat against other players, if/when AI is activated in some of these...
20 hours ago
by Due Diligence
17
The order size is large, but so was the increase in inventory value in Q1. The order doesn’t actually change anything that the company hasn’t consistently communicated throughout the beginning of the year. And yet, everyone is always surprised. Fortunately, the order can be delivered...
3 hours ago
by Dr.Feelgood
15
stock rocket ready; if a deal like this doesn’t lift the valuation of a completely beaten-down company, then nothing will. Happily holding until a future M&A. edit 11/12/2024 Optomed’s share price rattled the €5 mark following a previous large deal, and back then the cash position...
19 hours ago
by Velkku
15
Read more on our forum
Juha Kinnunen
Juha Kinnunen

Analyst

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.8.
2026

Interim report Q2'26

6.11.
2026

Interim report Q3'26

Regulatory press release6/18/2026, 2:30 PM

Inside Information: Optomed receives a large order in the US

Optomed
Press release5/11/2026, 1:16 PM

Redeye: Optomed (Q1 Interview): Expecting normalised sales in upcoming quarters

Optomed
Regulatory press release5/8/2026, 5:00 PM

Optomed Oyj: Decisions of the Organization Meeting of Optomed's Board of Directors

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release5/8/2026, 11:30 AM

Optomed Oyj: Decisions of the Annual General Meeting

Optomed
Press release5/8/2026, 8:10 AM

Redeye: Optomed (Q1 Review): Soft sales weigh on sentiment

Optomed
Press release5/6/2026, 8:51 AM

Redeye: Optomed (Q1 Initial take): Softer quarter than expected

Optomed
Regulatory press release5/6/2026, 6:00 AM

Optomed Oyj: Optomed Plc: Interim report January - March 2026

Optomed
Regulatory press release4/9/2026, 10:00 AM

Optomed Oyj: Notice Of The Annual General Meeting Of Optomed Plc

Optomed
US market roadmap for medical devices – a European perspective
Analyst Comment3/27/2026, 10:45 AM by
Antti Siltanen

US market roadmap for medical devices – a European perspective

Success in the US requires success in several sub-areas.

BioretecAiforia TechnologiesNightingale HealthNexstimOptomedRevenio GroupModulightBiohit
Regulatory press release2/27/2026, 7:00 AM

Optomed Oyj: Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed
Regulatory press release2/25/2026, 7:00 AM

Optomed Oyj: Optomed Annual Report 2025 published

Optomed
Press release2/11/2026, 12:31 PM

Redeye: Optomed Q4 (Review): Devices segment supports outlook despite cautious guidance

Optomed
Press release2/10/2026, 12:16 PM

Redeye: Optomed Q4 (Initial take): Sales in line; EBIT impacted by a one-off cost

Optomed
Regulatory press release2/10/2026, 7:00 AM

Optomed Oyj: Optomed Plc: Financial Statements Bulletin January - December 2025

Optomed
Regulatory press release1/29/2026, 11:30 AM

Optomed Oyj: Proposal of Optomed's Nomination Board

Optomed
Press release1/21/2026, 9:00 AM

Optomed Oyj: Optomed Achieves ISO 27001 Certification for Information Security Management Systems

Optomed
Press release1/12/2026, 7:00 AM

Optomed Oyj: Optomed and Aireen Announce Strategic Partnership and Achieve Approval for AI-Powered Handheld Diabetic Retinopathy Screening

Optomed
Life Science Companies as Investments | Life Science Night Dec. 9, 202514:40
Video12/16/2025, 7:30 AM

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland
Regulatory press release12/12/2025, 1:45 PM

Optomed Oyj: New shares subscribed for in Optomed Plc's directed share issue have been registered in the Finnish Trade Register

Optomed
Regulatory press release12/10/2025, 8:00 PM

Optomed Oyj: Inside information: Optomed Plc successfully completes directed share issue raising approximately EUR 6.0 million

Optomed